Quantcast

Empagliflozin vs canagliflozin

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

Pharmacy Kid

LCDR
10+ Year Member
Joined
Jun 7, 2008
Messages
779
Reaction score
237

Members don't see this ad.
Empagliflozin has shown to reduce the risk of cardiovascular death in diabetics with cvd, while canagliflozin has an increased risk of bone fractures and leg/foot amputations. Would any prescribers initiate canagliflozin over Empagliflozin knowing this? Do you think canagliflozin will fall off the market eventually?
 
Joined
Jan 7, 2011
Messages
1,103
Reaction score
1,349
I wonder if over the next few years studies will come out stating that Invokana (and/or Farxiga) is non-inferior to Jardiance with regard to cardiovascular risk reduction. Wouldn't be surprising.

Either way, as the first drug in class to hit the US market , and since I dispense more of it than the other drugs in class, I don't see it going away any time soon.
 
  • Like
Reactions: 1 users

Old Timer

Full Member
15+ Year Member
Joined
May 16, 2007
Messages
4,461
Reaction score
1,624
Empagliflozin has shown to reduce the risk of cardiovascular death in diabetics with cvd, while canagliflozin has an increased risk of bone fractures and leg/foot amputations. Would any prescribers initiate canagliflozin over Empagliflozin knowing this? Do you think canagliflozin will fall off the market eventually?
The Canvas Study published in the NEJM in June showed Invokana also reducted the risk of CVD. It does have increased incidence of amputation. The problem is these drugs are new and we don't know what time will show.
 
  • Like
Reactions: 2 users
Top